NIBEC is South Korea based biotech and pharma for development of peptide drug, drug delivery platform in regenerative medicine, reverse-age technology. New therapeutic target engaged peptide drug has been completed its phase I study in the area of obesity treatment, neurology. For the treatment of sarcopenia and pulmonary arterial hypertension (PAH), new modality based on the peptide is in the development. In addition to the peptide drug, oral drug delivery formulation and long acting formulation for the peptide drug are our another part of collaboration opportunities. NIBEC also provides the regenerative medical products for both human and animal healthcare including collagen products and oral care products.